ImmunoPrecise Antibodies Ltd. has announced groundbreaking results from a new validation study of their LENSai epitope mapping platform. This research confirmed the platform's ability to accurately predict antibody binding on 17 previously unseen antibody-antigen complexes, achieving near-crystallography precision without prior training data. The achievement underscores LENSai's capability to generalize across diverse biological structures, demonstrating true generalization rather than memorization. With these results already presented, ImmunoPrecise is poised to accelerate drug discovery processes, offering significant benefits to partners and investors in the biotech and pharmaceutical sectors.